

ML327

Catalog No: tcsc0023395

Available Sizes

Size: 1mg

Size: 5mg

Size: 25mg

Size: 50mg

Size: 100mg

Size: 100mg

Size: 100mg

Size: 100mg

Formula:

 $\mathsf{C}_{19}\mathsf{H}_{18}\mathsf{N}_4\mathsf{O}_4$

Pathway:

Apoptosis

Target:

c-Myc

Purity / Grade:

>98%

Solubility: DMSO : 32 mg/mL (87.34 mM; Need ultrasonic and warming)

Observed Molecular Weight:

366.37

Copyright 2021 Taiclone Biotech Corp.



Product Description

ML327 is a blocker of **MYC** which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).

IC50 & Target: MYC^[1]

In Vitro: Treatment with ML327 induces an elongated morphology in neuroblastoma cells. BE(2)-C cells treated with ML327 demonstrates G1 cell cycle arrest with a concordant decrease in S phase population, and a significant increase in the sub G0 population. ML327 induces the expression of *CDH1* in all seven of the neuroblastoma cell lines with a 50 to 1,400-fold induction of *CDH1* mRNA expression. ML327 blocks the expression of MYC family of oncogenic transcription factors in all tested neuroblastoma cell lines. Immunoblotting time course demonstrates early repression of N-MYC expression within 2 h of treatment with ML327 (10 μ M). p53 levels are also suppressed by treatment with ML327. ML327-pretreated cells demonstrates reduced proliferative potential in both tetrazolium-based (p[1]. ML327 reduces SW620inv cell invasion through Matrigel by ~60% and reduces H520 cell invasion by ~30% in these *in vitro* assays. ML327 partially restores E-cadherin expression at the plasma membrane in NMuMG cells induced to undergo Epithelial-to-Mesenchymal Transition (EMT) by TGF- β 1 treatment^[2].

In Vivo: ML327 treatment significantly reduces tumor volume by three-fold over the two-week treatment period (p=0.02). Tumor explant weights are approximately three-fold smaller in the ML327-treated mice (p=0.01). Mice treated with ML327 lost 12% more body weight than vehicle treated mice. ML327 treatment results in a two-fold decrease in *MYCN* expression, confirming that ML327 inhibits xenograft *MYCN* expression (p=0.0035)^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.